{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 30,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "other",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 7,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/13",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.61,
        "w": 0.86,
        "x": 0.085,
        "y": 0.245
      },
      "kind": "chart",
      "text": "Bar chart showing PE Scale (0-100) on the y-axis and different dosing regimens (6mg, 12mg, 18mg) for patients P21, P19, P22, and P20 on the x-axis. A PE Threshold is marked at 75.",
      "attrs": {
        "data_series": [
          {
            "label": "P21 - 6mg",
            "value": 96
          },
          {
            "label": "P19 - 6mg",
            "value": 47
          },
          {
            "label": "P19 - 12mg",
            "value": 97
          },
          {
            "label": "P22 - 6mg",
            "value": 73
          },
          {
            "label": "P22 - 12mg",
            "value": 83
          },
          {
            "label": "P20 - 6mg",
            "value": 28
          },
          {
            "label": "P20 - 12mg",
            "value": 45
          },
          {
            "label": "P20 - 18mg",
            "value": 77
          }
        ],
        "x_axis_label": "Dosing Regimen / Patient",
        "y_axis_label": "PE Scale"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0678ceae-4cb8-43ae-baee-b90cc223efd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.149,
        "x": 0.81,
        "y": 0.04
      },
      "kind": "image",
      "text": "GH Research",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7df8dcb6-1000-4245-ab40-0601f424adc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.018,
        "x": 0.94,
        "y": 0.94
      },
      "kind": "other",
      "text": "13",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ecbebb1-e1ad-42f3-9119-63adc75e0c52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.109,
        "x": 0.067,
        "y": 0.883
      },
      "kind": "source-note",
      "text": "PE, Peak Experience",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66a8f485-5fbe-41ea-af45-61cefc8c3401",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.149,
        "x": 0.034,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "2023© GH Research PLC",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f25fbe81-ae5d-45f2-9b85-741249466e7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.857,
        "x": 0.071,
        "y": 0.071
      },
      "kind": "title",
      "text": "Part B – Peak Experience (PE) Effect of Intraday Individualized Dosing Regimen (IDR)",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fb89359-3242-47eb-8837-8f0210d254a8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "5864143b-d19c-4942-a6ee-22b501a9b347",
      "evidence": "Bar chart showing PE Scale (0-100) on the y-axis and different dosing regimens (6mg, 12mg, 18mg) for patients P21, P19, P22, and P20 on the x-axis",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e59b812c-5781-40d1-880d-5eb666da502e",
      "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001",
      "position": 0,
      "objective": "Highlight the need for more effective depression treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}